Authors
Nimerchy M.A.1, Knyazeva A.I.1, Novikov V.M.2, Popkova P.M.2, Simonenko O.D.2
1 Volga Research Medical University, Nizhny Novgorod
2 Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky, Krasnoyarsk
Abstract
Rationale. Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by demyelination, axonal damage, and progressive neurological impairment.
Objective. The aim of this study is to analyze current literature data addressing the use of immunomodulatory therapy in the management of MS symptoms.
Methods. A literature review was conducted using sources published from 2019 to 2025 in PubMed, Scopus, Web of Science, and eLIBRARY.RU databases. The analysis included systematic reviews, meta-analyses, original research articles, and randomized controlled trials reporting data on the efficacy and safety of immunotherapy.
Results. It has been established that therapy with immunomodulatory agents and interferon-based drugs reduces the frequency of relapses and lesion activity on magnetic resonance imaging without significant adverse effects. Sphingosine-1-phosphate modulators have demonstrated efficacy in limiting lymphocyte migration and reducing inflammation in the central nervous system. Anti-CD20 monoclonal antibodies significantly reduce the risk of disability progression as well as the level of neurofilament light chain, which is considered a marker of neuroaxonal damage. Adverse effects associated with most therapies did not exceed control group values.
Conclusion. Immunomodulatory therapy in MS is effective in reducing the activity of the disease and the rate of progression of neurological deficits. Its effect on persistent symptoms such as cognitive impairment and fatigue requires further study.
Keywords: multiple sclerosis, immunomodulatory therapy, glatiramer acetate, sphingosine-1-phosphate, monoclonal antibodies, cognitive impairment, neurofilament.
References
1. Rasseyannyj skleroz / Vsemirnaya organizaciya zdravoohraneniya. https://www.who.int/ru/news-room/fact-sheets/detail/multiple-sclerosis.
2. Epedemiology / Atlas of MS. https://www.atlasofms.org/map/global/epidemiology/number-of-people-with-ms.
3. Suminov VV, Antsiferova EV. Comparison of the prevalence of multiple sclerosis in the Russian Federation and abroad. Proceedings of the XVIII International Burdenkov Scientific Conference, April 14-16, 2022. Voronezh: VSMU named after N.N. Burdenko. Youth Innovation Bulletin. 2022; XI(1): 314-317. (In Russ.)
4. Prokaeva AI, Arkhipov IE, Dorchinets EE, et al. Multiple sclerosis: modern diagnostic markers and prognostic factors of disease progression. Siberian Scientific Medical Journal. 2024; 44(1): 39-51. (In Russ.) doi: 10.18699/SSMJ20240105.
5. Statinova EA, Fominova NV, Sokhina VS. Current aspects of the etiology and pathogenesis of multiple sclerosis. Bulletin of Hygiene and Epidemiology. 2020; 24(2): 254-257. (In Russ.)
6. Bourque J, Hawiger D. Current and Future Immunotherapies for Multiple Sclerosis. Mo Med. 2021; 118(4): 334-339.
7. Mirabella M, Annovazzi P, Brownlee W, et al. Treatment challenges in multiple sclerosis – a continued role for glatiramer acetate? Frontiers in Neurology. 2022; 13. doi: 10.3389/fneur.2022.844873.
8. Wynn DR. Enduring clinical value of Copaxone® (glatiramer acetate) in multiple sclerosis after 20 years of use. Multiple Sclerosis International. 2019. doi: 10.1155/2019/7151685.
9. Coyle PK, Freedman MS, Cohen BA, et al. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review. Ann Clin Transl Neurol. 2024; 11(4): 842-855. doi: 10.1002/acn3.52017.
10. Bascuñana P, Möhle L, Brackhan M, et al. Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis. Drugs RD. 2020; 20(3): 197-207. doi: 10.1007/s40268-020-00316-1.
11. Goodman AD, Anadani N, Gerwitz L. Siponimod in the treatment of multiple sclerosis. Expert Opin Investig Drugs. 2019; 28(12): 1051-1057. doi: 10.1080/13543784.2019.1676725.
12. Lassiter G, Melancon C, Rooney T, et al. Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Neurol Int. 2020; 12(3): 89-108. doi: 10.3390/neurolint12030016.
13. Cao L, Li M, Yao L, et al. Siponimod for multiple sclerosis. Cochrane Database Syst Rev. 2021; 11(11): CD013647. doi: 10.1002/14651858.CD013647.
14. Comi G, Kappos L, Selmaj KW, et al. SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019; 18(11): 1009-1020. doi: 10.1016/S1474-4422(19)30239-X.
15. Awada Z, Hameed N, Harel A. Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy. Drug Des Devel Ther. 2024; 18: 5985-5996. doi: 10.2147/DDDT.S315174.
16. Hauser SL, Bar-Or A, Cohen J.A, et al. Ofatumumab versus Teriflunomide in multiple sclerosis. The New England Journal of Medicine. 2020; 383(6): 546-557. doi: 10.1056/NEJMoa1917246.
17. Kuhlmann T, Antel J. Multiple sclerosis: 2023 update. Free Neuropathol. 2023; 4: 3. doi: 10.17879/freeneuropathology-2023-4675.
